Michael Kevin Handley
DirectorMr. Michael Kevin Handley, also known as Mike, has been a Director of PetVivo Holdings, Inc. since September 22, 2026. He is Independent Director of Statera Biopharma, Inc. Mr. Handley served as President of Tivic Biopharma at Valion Bio, Inc. (formerly known as Tivic Health Systems, Inc.) since February 18, 2025 until March 3, 2026 and served as Chief Executive Officer from March 4, 2026 to August 16, 2026 and is its Director from March 3, 2026 and served as its Chief Operating Officer since February 18, 2025 until March 4, 2026. He has been President, Chief Executive Officer, Director and Chairman of the Board at Sparta Healthcare Acquisition Corp. (upon closing of the merger with old Cytocom) since July 27, 2021. Mr. Handley helped found Vessix Vascular, Inc. in 2011 and served as its Vice President of Clinical, Quality and Regulatory until its acquisition by Boston Scientific Corporation in 2012. He also served as Global Head of Regulatory at Acclarent, Inc. and held senior executive positions at Spectranetics Corporation, Accelapure Corporation, Genentech, Inc., Amgen Inc. and Gliatech Inc. Prior to that, he served in senior executive roles at Spectranetics, a medical device company and Accelapure Corporation, a biotechnology company. He had been a Director at Coeptis Therapeutics Inc. (formerly known as Vinings Holdings Inc.) (formerly known as Coeptis Pharmaceuticals, Inc.) since February 12, 2021 until April 4, 2022. Mr. Handley served as Chief Executive Officer of Aletheia Therapeutics, Inc. He served as Chief Executive Officer and Director of Statera Biopharma, Inc. (formerly known as Cytocom, Inc.) since July 27, 2021 and served as its President until February 2025. Mr. Handley serves as Chief Executive Officer and Chairman at Aletheia Therapeutics Corp. He served as Chief Executive Officer since September 20, 2019 until April 30, 2020 and Director of Immune Therapeutics, Inc. since July 2019 until March 2020 and served as President until April 30, 2020. Mr. Handley served as the Chief Executive Officer and Director of Armis Biopharma, Inc. (aka CHD Biosciences) since 2012 to 2018. In his role with Armis, Mr. Handley was responsible for day-to-day operations, executing a profitable growth strategy, obtaining global product approvals, overseeing intellectual property strategy, product commercialization, business development and financing. Prior to his work at Armis, Mr. Handley served in senior management roles at multiple life science companies. He served as Chief Development Officer of Reven Pharmaceuticals, Inc. and serves as its Director. He serves on the Board of Directors of Makamer, Inc and as a Manager of Palmera Singapore LLC. He has quality, clinical and regulatory experience in the healthcare field. He has been a life science business professional with cross-functional experience in drug/device commercialization, operations, mergers/acquisitions, regulatory/clinical affairs, venture formation/financing, market development and Partnering/licensing. He has founded multiple health industry enterprises and held executive, management and advisory positions in a substantial number of leading public and private pharmaceutical and biotechnology companies. He was a Senior Principal of PRTM Management Consultants, Inc. He has drug discovery experience including multiple patents and peer-reviewed publications in the areas of oncology and neuroscience. He has lead management teams in a variety of business capacities including development of global corporate strategies for numerous public and private biotechnology and pharmaceutical companies. He has assisted or led in the global commercialization of seventeen devices and drugs that account for sales annually. He has experience leading management teams in a variety of capacities in high growth organizations. Mr. Handley was one of the Founders and on the management team of Vessix Vascular, Inc. in Laguna Hills California from 2011 to 2012. He served as Vice President of Quality Clinical & Regulatory Affairs at Vessix Vascular, Inc. (acquired by Boston Scientific) since October 2010 until 2012. He served as a Director of Global Regulatory Affairs & Compliance and Chief Compliance Officer of The Spectranetics Corporation (acquired by Phillips). He served as Vice President of Global Regulatory Affairs & Compliance at The Spectranetics Corporation since January 2009 until 2010. Mr. Handley joined Spectranetics in 2007 as Manager of Regulatory Affairs and served as its Director, Global Regulatory Affairs & Compliance and Chief Compliance Officer. He was the Founder of AccelaPure Corporation and served as its Chief Executive Officer from May 2005 to February 2007 and was its Vice President of Regulatory Affairs. Mr. Handley was Global Head of Regulatory at Acclarent (that was acquired by Johnson & Johnson) from 2010 to 2011 and assisted in the integration of acquisition of Acclarent and their five product lines and driving the global revenue growth of the Ethicon franchise for ENT products. He founded and was Group Leader of the Accelerated Pipeline Chemistry Group at Amgen Inc., where he was instrumental in the advancement and development of AMG706 and Kit. Additionally, he played a major role in the discovery and development of the GT-2331/Cipralisant Maleate/Perceptin. He also founded BiophoriX. He has experience in the biopharmaceutical industry. He served as an Executive Affiliate/Senior Principal for the management-consulting firm Pittiglio Rabin Todd & McGrath (acquired by PricewaterhouseCoopers) from 2004 to 2005. He has worked in leadership roles at Johnson & Johnson, Genentech/Roche, PricewaterhouseCoopers/PRTM and Gliatech. Mr. Handley serves on the Board of Directors of Metabiostere, Inc., nanoPharmatix Inc. and Actus Partners. He serves as the President of the Northern Colorado Bioscience Association and is an Executive-in-Residence at the Rocky Mountain Innersphere. He assisted in the launch of Avastin and Tarceva at Genentech. He attended the Executive MBA program at Pepperdine University and completed the Global C-Suite Program at the Wharton School of the University of Pennsylvania. He has served on corporate and nonprofit boards, taught in Colorado State University’s Regulatory Affairs Program, lectured at Drexel University’s LeBow College of Business and is an inventor and author of issued patents, published patent applications and peer-reviewed scientific publications.He holds Board positions at Medavate Corp. and Symbios Technologies, Inc. Mr. Handley graduated with honors from Colorado State University with Bachelor of Science degrees in Molecular Biology, Physiology and minors in Chemistry and Neurobiology in 1995. He transferred to Colorado State University from University of Southern California (1989 – 1992) where he was a Presidential Scholar and Aerospace Engineering Major Mr. Handley has an executive MBA program from the Graziadio School of Business and Management at Pepperdine University
Positions
- Company NameValion Bio, Inc.Stock CodeVBIOPositionDirector
